Docetaxel Non-Alcohol Formula FDA Approval History
FDA Approved: Yes (First approved December 22, 2015)
Brand name: Docetaxel Non-Alcohol Formula
Dosage form: Injection
Company: Eagle Pharmaceuticals, Inc.
Treatment for: Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Gastric Cancer, Head and Neck Cancer
Docetaxel Injection, Non-Alcohol Formula is an alcohol-free formulation of docetaxel for use in the treatment of patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
The approval of a non-alcohol formula follows a warning from the U.S. Food and Drug Administration (FDA) advising patients and healthcare professionals that intravenous docetaxel formulations (Taxotere, Docefrez and generics) contain ethanol (alcohol), which may cause patients to experience intoxication or feel drunk during and after treatment.Development timeline for Docetaxel Non-Alcohol Formula
| Date | Article |
|---|---|
| Dec 28, 2015 | Approval Teikoku Pharma USA, Inc. Announces FDA Approval of Docetaxel Injection, Non-Alcohol Formula |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
